[{"arm_notes": "", "treatment_id": null, "treatment_name": "Jusvinza; CIGB-258\r;Administration; Intravenous;Respiration; Artificial;Peptides;- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning, administer 1 mg intravenously every 24 hours for three days. If there is no clinical, gasometric and radiological improvement after 24-48 hours, the dose can be increased to 2 mg, with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.", "treatment_id": 2044, "treatment_name": "Jusvinza", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}, {"arm_notes": "Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy, or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical, gasometric and radiological improvement (or earlier, if the patient requires mechanical ventilation), the dose can be increased to 2 mg, with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical, gasometric and radiological improvement is observed, the doctor may consider suspending this therapy or not (and start another treatment out of protocol). -", "treatment_id": 2044, "treatment_name": "Jusvinza", "treatment_type": "Anti-inflammatories", "pharmacological_treatment": "Pharmacological treatment"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Jusvinza; CIGB-258\r;Administration; Intravenous;Respiration; Artificial;Peptides;- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258\r;- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "14", "treatment_id": 287, "treatment_name": "Cigb-258", "treatment_type": "Other targeted therapies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "14", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).- Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS.Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg.If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol).-", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Respiration; Artificial;Administration; Intravenous;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": null, "treatment_name": "- Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS. Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol). - Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group I: CIGB-258 peptide (Jusvinza; CIGB; Havana; Cuba) + standard therapy according to the interim algorithms for the care of COVID-19 established by the IMSS. Patients WITH mechanical ventilation: 1 mg intravenously every 12 hours until extubation of the patient. After weaning; administer 1 mg intravenously every 24 hours for three days. If there is no clinical; gasometric and radiological improvement after 24-48 hours; the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. Patients WITHOUT mechanical ventilation: 1 mg intravenously every 12 hours until the patient reverses his condition (no need for oxygen therapy; or signs and / or symptoms of acute respiratory failure). If at 72 hours there is no clinical; gasometric and radiological improvement (or earlier; if the patient requires mechanical ventilation); the dose can be increased to 2 mg; with a frequency of 12 hours (at the discretion of the practitioner). Total dose / day: 4 mg. If after the 7th day of a patient receiving the maximum dose of CIGB-258 peptide (2 mg every 12 hours) no clinical; gasometric and radiological improvement is observed; the doctor may consider suspending this therapy or not (and start another treatment out of protocol). -", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group II (Control): Standard therapy according to the interim algorithms for COVID-19 care established by the IMSS.;Peptides;Jusvinza; CIGB-258", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]